Today: 7 February 2026
Subscribe
Browse Category

NYSE:ABBV News 8 January 2026 - 15 January 2026

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

New York, Jan 14, 2026, 19:30 EST — After-hours AbbVie Inc’s shares climbed roughly 0.5% to $221.89 in after-hours trading Wednesday, following executives’ announcement to expand the company’s footprint in obesity treatments. During the regular session, the stock fluctuated between $217.84 and $223.27. The timing is crucial. AbbVie continues to push for growth beyond its legacy blockbusters as biosimilar competition intensifies — these cheaper copies of complex biologic drugs usually drive prices down. Investors are still ready to pay a premium for weight-loss drugs, even those early in development and costly. AbbVie is entering the fray belatedly, and Wall Street
15 January 2026
···
Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

New York, Jan 14, 2026, 11:23 EST — Regular session Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%. Healthcare outperformed the broader market. The Health Care Select Sector SPDR ETF edged up slightly, with Merck, Pfizer, and AbbVie each adding about 0.6%, 0.6%, and 0.5%, respectively. Shares are climbing again amid fresh legal developments ahead of next week’s earnings. Delaware’s Supreme Court on Monday threw out part of a September 2024 ruling over “milestone” payments tied to J&J’s $3.4 billion Auris Health acquisition in 2019. The
14 January 2026
········
AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

AbbVie stock nudges lower after Trump drug-price pact; traders watch JPM talk, Feb. 4 results

New York, January 13, 2026, 14:45 ET — Regular session AbbVie shares slipped 0.1% to $219.83 Tuesday afternoon after the drugmaker announced a three-year deal with the Trump administration. The pact aims to lower certain drug prices in return for exemptions from tariffs and future pricing rules. The deal arrives amid investor attempts to figure out how “lower prices” might impact big pharma in 2026 — and if Washington’s efforts will become a serious drag on margins or just a tolerable hit. It also brings trade policy into the pricing debate, a spot few shareholders anticipated focusing on this early
13 January 2026
·····
AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

AbbVie stock flat after-hours as TrumpRx pricing deal and RemeGen cancer pact land

New York, Jan 12, 2026, 19:48 EST — After-hours AbbVie shares barely moved in after-hours Monday following a new three-year pricing pact with the Trump administration. The drugmaker also announced two deals to strengthen its pipeline and boost U.S. manufacturing. The stock slipped less than 0.1% to $220.04. The timing is crucial as Washington ramps up pressure on drugmakers over pricing, while trade policy and tariffs linger in corporate discussions. Investors are sorting out which costs are truly significant versus just noise. AbbVie’s moves bring policy risk, dealmaking, and capital spending into one sharp focus. With earnings season approaching for
13 January 2026
·····
AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

AbbVie stock slips after $650 million RemeGen cancer-drug deal and Arizona plant buy

New York, January 12, 2026, 13:31 EST — Regular session AbbVie Inc shares slipped Monday following news of a new collaboration with China’s RemeGen to co-develop an experimental solid-tumor drug, as the company ramps up efforts to expand its cancer portfolio via licensing deals. By 1:30 p.m. EST, AbbVie was down 0.6% at $218.81. (Reuters) Investors are focused on how fast AbbVie can transform its oncology pipeline into a real growth driver instead of just another distant promise. The company said the drug could create new combination opportunities with its antibody-drug conjugates, or ADCs — targeted cancer therapies linking an
12 January 2026
·····
AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

AbbVie stock heads into JPM Healthcare week as $30B deal talk creeps back

New York, January 11, 2026, 11:10 EST — Market closed AbbVie Inc. (ABBV.N) closed Friday down 1.8% at $220.08. As U.S. markets remain closed over the weekend, chatter about a potential deal lingers heading into Monday. The J.P. Morgan Healthcare Conference week draws attention now, serving as a hotspot for new guidance, pipeline updates, and those crucial side-room talks that often spark M&A activity. For major drugmakers, it’s also the moment investors demand a clear answer: should they buy growth or build it themselves? Deal advisers told Reuters they expect a surge in large healthcare M&A deals in 2026 as
11 January 2026
····
Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

Healthcare stocks face JPMorgan conference pressure as XLV slips and deal talk builds

NEW YORK, Jan 10, 2026, 13:31 EST — Market closed U.S. healthcare stocks ended the week weaker, with the Health Care Select Sector SPDR Fund (XLV) slipping 0.5% to $157.31 on Friday. This ETF, often seen as a benchmark for major U.S. healthcare companies, has shown volatility as investors brace for a packed schedule of sector developments. The industry’s annual dealmaking and investor tour is about to ramp up, and healthcare’s stakes are high. Traders are debating if this year will see a surge in biotech and medtech acquisitions, and whether major drugmakers move from discussion to actual deals. The
10 January 2026
······
AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

AbbVie stock slips into weekend after $1.3 billion charge resets guidance; JPM conference looms

NEW YORK, January 10, 2026, 11:17 AM EST — The market has closed. Shares of AbbVie Inc slipped 1.8% to close Friday at $220.08, wrapping up a choppy session marked by shifting guidance and takeover rumors. AbbVie disclosed in a regulatory filing that it anticipates around $1.3 billion in acquired in-process research and development (IPR&D) and milestone expenses in Q4—costs associated with upfront charges for buying or licensing drug projects. This will slash earnings by approximately 71 cents per share. The company also cut its Q4 adjusted EPS forecast to $2.61-$2.65 from $3.32-$3.36 and trimmed its full-year 2025 adjusted EPS
10 January 2026
·····
AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

AbbVie stock slips after $1.3 billion R&D charge and Revolution Medicines rumor — what investors watch next

New York, January 9, 2026, 20:18 (EST) — Market closed AbbVie Inc. shares dropped 1.8% on Friday, closing at $220.08. The decline followed the drugmaker’s decision to lower its 2025 earnings forecast and a denial of reports suggesting it was in talks to acquire cancer-drug developer Revolution Medicines. Since 2023, AbbVie has spent over $20 billion on acquisitions, aiming to offset the impact from Humira’s patent expiration. (Reuters) The updated forecast is crucial since AbbVie’s deals aim to replace lost growth, and this charge came late in the year when investors were already preparing for a rough transition from aging
10 January 2026
······
AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

AbbVie stock slips on $1.3B charge, deal-rumor denial — what’s next for ABBV

NEW YORK, Jan 9, 2026, 12:28 PM EST — Regular session AbbVie Inc (ABBV) shares fell about 0.8% in midday New York trade on Friday after the drugmaker trimmed its 2025 profit outlook and brushed off a report tying it to a takeover of cancer biotech Revolution Medicines. The stock was down $1.78 at $222.35. AbbVie said in an emailed statement that it “is not in discussions with Revolution Medicines” and has spent more than $20 billion on acquisitions since 2023 as it tries to replace sales lost after Humira’s U.S. patent protection ended. (Reuters) The warning lands just ahead
9 January 2026
·····
AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

AbbVie stock slides on $1.3 billion charge and outlook cut as deal chatter swirls

New York, Jan 8, 2026, 19:33 EST — After-hours AbbVie shares dropped 4% on Thursday, slipping to $224.13 in after-hours trading from a previous close of $233.41, as investors digested a profit forecast reduction linked to a hefty charge. The move matters because AbbVie is scrambling to make up lost ground after Humira’s patent expired, leaning heavily on acquisitions to sustain its growth. Traders have been quick to pounce on any whispers of another big deal, especially after takeover chatter about cancer-drug developer Revolution Medicines briefly lifted AbbVie shares just a day before. Reuters AbbVie revealed in a filing that
9 January 2026
·····
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

New York, January 8, 2026, 13:12 ET — Regular session AbbVie Inc shares fell on Thursday after the drugmaker denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge that will dent its 2025 profit outlook. AbbVie stock (ABBV) was down 3.7% at $224.84 at 1:12 p.m. ET, after swinging between $231.93 and $223.84. The decline takes steam out of a rally sparked by a Wall Street Journal report that AbbVie was in advanced talks to buy Revolution Medicines. AbbVie told Reuters it “is not in discussions with Revolution Medicines,” and also trimmed its 2025 profit forecast
8 January 2026
······
1 2 3 4 5 … 7

Stock Market Today

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

Seagate (STX) stock jumps nearly 6% as Citi hikes target — what to watch next week

7 February 2026
Seagate shares rose 5.9% to $429.32 Friday after Citigroup raised its price target to $480 and reiterated a buy rating. The gain ended a two-day slide but left the stock 6.6% below its Feb. 3 high. CEO Dave Mosley sold 20,000 shares on Feb. 2 under a pre-arranged plan, SEC filings show. U.S. jobs and inflation data next week are seen as key tests for tech stocks.
Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop